Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2020 - 12 - 01 save search
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant
Published: 2020-06-19 (Crawled : 22:16) - globenewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 5.38%
H: 9.42%
C: 1.16%
covid biopharma vaccine trial phase 3 phase 1 phase 2
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant
Published: 2020-07-14 (Crawled : 22:16) - globenewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 2.47%
H: 5.5%
C: 5.39%
covid vaccine trial phase 3 phase 1 phase 2
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.79%
H: 6.33%
C: 2.38%
treatment phase 3 phase 1 phase 2 nivolumab
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
Published: 2020-07-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.07%
H: 4.7%
C: 2.69%
risk results leukemia research phase 3 phase 1 phase 2
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Published: 2020-09-21 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 24.3%
H: 9.9%
C: -9.03%
china biopharma trial phase 3 phase 1 phase 2
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
Published: 2019-03-20 (Crawled : 22:14) - globenewswire.com
APVO | $0.6827 -7.27% -7.84% 570K
|
Health Technology
|
| O: 5.3%
H: 5.62%
C: -6.18%
disease antibody trial treatment phase 3 phase 1 phase 2
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
Published: 2020-12-01 (Crawled : 22:10) - globenewswire.com
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
|
| O: 0.81%
H: 7.51%
C: 1.88%
cancer trial expansion phase 2
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion
Published: 2020-12-01 (Crawled : 22:00) - biospace.com/
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
|
| O: 0.81%
H: 7.51%
C: 1.88%
cancer trial expansion phase 2
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
Published: 2020-12-01 (Crawled : 21:02) - globenewswire.com
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: 0.0%
H: 2.34%
C: -1.68%
trial phase 2 pharma
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Published: 2020-12-01 (Crawled : 21:02) - globenewswire.com
GLPG | News | $28.78 -2.28% -2.33% 140K
|
Health Technology
|
| O: -1.98%
H: 0.95%
C: 0.12%
disease trial phase 2 kidney
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.